SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

Core Insights - Complete Genomics and SOPHiA GENETICS have announced a collaboration to co-market MSK-ACCESS® and MSK-IMPACT® powered by SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, aiming to enhance access to precision oncology testing globally [1][2]. Group 1: Collaboration Details - The partnership integrates SOPHiA GENETICS' AI-powered applications with Complete Genomics' DNBSEQ-T1+ platform, providing a sample-to-report workflow for laboratories [2]. - This collaboration marks a significant expansion into the precision oncology research market, enhancing the capabilities of both companies [2][3]. Group 2: Technology and Performance - The DNBSEQ-T1+ platform offers Q40-level accuracy and optimized throughput ranging from 500 million to 2 billion reads per flow cell, with a 24-hour paired-end 150bp run time [3]. - Each flow cell can run up to 60 tumor-normal sample pairs for tissue and up to 16 for liquid biopsy, providing a cost-effective and flexible sequencing solution [3]. Group 3: Benefits and Impact - The collaboration aims to enable decentralized labs to deliver faster, more accurate, and affordable insights to clinicians and researchers [3]. - SOPHiA DDM™ is a technology-agnostic analytics platform that enhances the analysis of healthcare data, demonstrating lower background noise and reduced turnaround time compared to other systems [4]. Group 4: Market Positioning - This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path for implementing comprehensive genomic profiling in precision oncology research [5]. - The collaboration is positioned to broaden access to data-driven medicine, allowing more laboratories worldwide to adopt precision oncology solutions [3][4].